Novartis, Molecular Partner team up on COVID-19 candidates
ZURICH, Oct 28 (Reuters) - Novartis NOVN.S has licenced global rights to two Molecular Partners MOLN.S antiviral drugs that have potential to treat COVID-19 patients, the two companies said on Wednesday.
Molecular Partners will get an upfront payment of 60 million Swiss francs ($66.2 million), a potential milestone payment of 150 million francs, and a "significant royalty" on sales of the drugs called MP0420 and MP0423.
($1 = 0.9070 Swiss francs)
(Reporting by John Miller)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.